UDK: 616.279-008.64«470.45»

INFLUENCE OF LONG TERM THERAPY WITH SULPHONYLUREA DERIVATIVES ON THE CAPACITY OF THE HEPATIC CYP2C9 ENZYME SYSTEM OF DRUG BIOTRANSFORMATION IN DIABETIC TYPE II PATIENTS IN THE CITY OF VOLGOGRAD

V. I. Petrov, N. V. Rogova, Y. M. Ledyaev, D. M. Serdukova

Кафедра клинической фармакологии ВолГМУ

Abstract

It is shown that long-standing type II diabetes mellitus leads to the reduced CYP2C9 capacity. There has been obtained strong evidence that long term administration of sulphonylurea derivatives reduces the CYP2 C9 capacity by significantly altering pharmacokinetics of the drugs. This requires a change in their dosing regimen . Mandatory pharmacokinetic typing of CYP2C9 activity should be recommended to improve the efficacy of pharmacotherapy for type II diabetes mellitus, to prevent the undesirable adverse reactions when taking the drugs and to reduce the treatment cost for this group of patients.

Keywords

type II diabetes, pharmacokinetic typing, the capacity of the hepatic CYP2C9 enzyme system, enhancement of pharmacotherapy, long term administration of sulphonylurea derivatives

Contacts

Рогова Наталья Вячеславовна — к. м. н., доцент кафедры клинической фармакологии и интенсивной терапии с курсами клинической фармакологии ФУВ, клинической аллергологии ФУВ, восстановительной терапии и курортологии ФУВ ВолГМУ, (8442) 43-30-60, 43-60-36, nvr